title: Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma.
abstract: Perioperative chemotherapy provided to increase the chance of cure for localized disease and maintenance therapy for metastatic disease represent 2 distinct aspects of the urothelial cancer disease treatment spectrum. The ability to access both pre- and postchemotherapy tissue in the neoadjuvant setting provides important opportunities for translational research to test novel therapies and identify predictors of response to therapy. The maintenance setting may be more complex, and study design and endpoints need to be determined on the basis of the candidate drugs' mechanisms of action and toxicity.
authors.affiliation: Department of Medical Oncology, Thomas Jefferson University School of Medicine, Philadelphia, PA.
authors.forename: Jean
authors.initials: J
authors.lastname: Hoffman-Censits
authors.affiliation: Department of Medical Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA. Electronic address: yu-ning.wong@fccc.edu.
authors.forename: Yu-Ning
authors.initials: YN
authors.lastname: Wong
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D060046:Maintenance Chemotherapy; D058990:Molecular Targeted Therapy; D059035:Perioperative Period; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: Adjuvant therapy; Maintenance therapy; Neoadjuvant chemotherapy; Targeted therapy; Urothelial cancer